In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii

References

• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582.18625687
   PubMed Web of Science ®Google Scholar
• Neill JO. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;4:1–16.
   Google Scholar
• Zhou H, Yang Q, Yu Y, Wei Z, Li L. Clonal spread of imipenem- resistant Acinetobacter baumannii among different cities of China. J Clin Microbiol. 2007;45(12):4054–4057. doi:10.1128/JCM.00343-0717942662
   PubMed Web of Science ®Google Scholar
• Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692–699. doi:10.1086/50020216447117
   PubMed Web of Science ®Google Scholar
• Antunes LCS, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301. doi:10.1111/2049-632X.1212524376225
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator - associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416. doi:10.1164/rccm.200405-644ST15699079
   PubMed Web of Science ®Google Scholar
• Mangoni ED, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–358. doi:10.1093/cid/cit25323616495
   PubMed Web of Science ®Google Scholar
• Chuang Y, Cheng C, Sheng W, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug- resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102. doi:10.1186/1471-2334-14-10224564226
   PubMed Web of Science ®Google Scholar
• Galani I, Kontopidou F, Souli M, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Ag. 2008;31(5):434–439. doi:10.1016/j.ijantimicag.2008.01.011
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemoth. 2008;62(Supplement 1):i11–6. doi:10.1093/jac/dkn242
   Web of Science ®Google Scholar
• Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis. 1993;167(2):448–451. doi:10.1093/infdis/167.2.4488421178
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2002;46(6):1946–1952. doi:10.1128/AAC.46.6.1946-1952.200212019113
   PubMed Web of Science ®Google Scholar
• Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, Pachón J, Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother. 2006;58(3):689–692. doi:10.1093/jac/dkl30316870647
   PubMed Web of Science ®Google Scholar
• Harris G, Kuo Lee R, Lam CK, et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013;57(8):3601–3613. doi:10.1128/AAC.00944-1323689726
   PubMed Web of Science ®Google Scholar
• Ma X, Guo Y, Wu Y, Gong W, Sun J, Huang Z. In vivo bactericidal effect of colistin–linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia. Sci Rep-Uk. 2020;10(1):1–8.
   PubMed Web of Science ®Google Scholar
• Ku NS, Lee S, Lim YS, et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep-Uk. 2019;9(1):1–7.
   Google Scholar
• Institute CALS. Performance standards for antimicrobial susceptibility testing. Clin Microbiol Newsletter. 2019;23(6):M100–M111.
   Google Scholar
• Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007;45(1):227–230. doi:10.1128/JCM.01588-0617093026
   PubMed Web of Science ®Google Scholar
• Phee L, Hornsey M, Wareham DW. In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. Eur J Clin Microbiol. 2013;32(10):1291–1294. doi:10.1007/s10096-013-1875-z
   Google Scholar
• Manepalli S, Gandhi JA, Ekhar VV, Asplund MB, Coelho C, Martinez LR. Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis. J Med Microbiol. 2013;62(11):1747–1754. doi:10.1099/jmm.0.060004-024000227
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Fujikawa T, Kanazawa K, Yamaguchi K. In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including -lactamase-negative ampicillin-resistant strains. J Antimicrob Chemother. 2001;48(5):723–726. doi:10.1093/jac/48.5.72311679563
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Ag. 2009;33(1):33–39. doi:10.1016/j.ijantimicag.2008.07.008
   Web of Science ®Google Scholar
• van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun. 2007;75(12):5597–5608. doi:10.1128/IAI.00762-0717908807
   PubMed Web of Science ®Google Scholar
• Ozturk S, Ustun C, Pehlivan S, Ucak H. Acute generalized exanthematous pustulosis associated with tigecycline. Ann Dermatol. 2014;26(2):246–249. doi:10.5021/ad.2014.26.2.24624882982
   PubMed Web of Science ®Google Scholar
• Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21.26862399
   PubMed Web of Science ®Google Scholar
• Li WY, Brien-Simpson NMO, Holden JA, et al. Holden Covalent conjugation of cationic antimicrobial peptides with a β‐lactam antibiotic core[J]. Pept Sci. 2018;110(3). doi:10.1002/pep2.24059
   Web of Science ®Google Scholar
• Desgranges S, Ruddle CC, Burke LP, et al. β-Lactam-host defence peptide conjugates as antibiotic prodrug candidates targeting resistant bacteria. RSC Adv. 2012;2(6):2480–2492. doi:10.1039/c2ra01351g
   Web of Science ®Google Scholar
• Schneider EK, Reyes-Ortega F, Velkov T, Li J. Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative “superbugs”. Essays Biochem. 2017;61(1):115–125. doi:10.1042/EBC2016005828258235
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):1119–1125. doi:10.1093/jac/dkq10820378670
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/S1473-3099(18)30099-929456043
   PubMed Web of Science ®Google Scholar
• Liu Q, Li W, Feng Y, Tao C. Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis. PLoS One. 2014;9(6):e98091. doi:10.1371/journal.pone.009809124911658
   PubMed Web of Science ®Google Scholar
• Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents. 2013;41(2):110–116. doi:10.1016/j.ijantimicag.2012.09.00523127485
   PubMed Web of Science ®Google Scholar
• Shen F, Han Q, Xie D, Fang M, Zeng H, Deng Y. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;39:25–33. doi:10.1016/j.ijid.2015.08.00926283551
   PubMed Web of Science ®Google Scholar
• Chiang S, Tang H, Chen C, et al. Acid aspiration provokes the pneumonia caused by multidrug-resistant Acinetobacter baumannii in BALB/c mice. Int J Infect Dis. 2013;17(6):e454–60. doi:10.1016/j.ijid.2013.01.02223522637
   PubMed Web of Science ®Google Scholar
• Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25(6):523–529. doi:10.1016/j.ijantimicag.2005.02.01315885987
   PubMed Web of Science ®Google Scholar